Team:Evry/HumanPractice/Expert consultation/vf

From 2013.igem.org

(Difference between revisions)
(Created page with "{{:Team:Evry/vf/template_practice}} <html> <div id="mainTextcontainer"> <h1>Consultation d'experts</h1> <p><em>Lors de ce projet, nous avons établi un contact avec différen...")
Line 8: Line 8:
<p><em>Lors de ce projet, nous avons établi un contact avec différents experts de l'hémochromatose : des patients, des chercheurs spécialistes du métabolisme du fer et des cliniciens.</em></p>
<p><em>Lors de ce projet, nous avons établi un contact avec différents experts de l'hémochromatose : des patients, des chercheurs spécialistes du métabolisme du fer et des cliniciens.</em></p>
 +
 +
<h2>The scientific point of view</h2>
 +
 +
<img src='http://2013.igem.org/wiki/images/7/76/GN.jpg' alt='Gaël Nicolas' align='left' style="margin-right:20px;" height='200px'/>
 +
<p>Professor Gaël Nicolas is a French scientist who is working on the regulation of hepcidin expression. He described in 2001 for the first time the role of this hormone in the regulation of iron homeostasis in mammals. <br>
 +
<small>(See <a href='http://cvscience.aviesan.fr/cv/76/gael-nicolas' target='_blank'>Gaël Nicolas resume</a> for more information)</small><br/><br/>
 +
The meeting took place at Cochin Institut, on the 18 June 2013.</p><br/>
 +
 +
<p>We first presented the aim of iGEM competition and iGEM Evry team to Gaël Nicolas. We mentioned the pluridisciplinary aspect of iGEM: biology, engineering, mathematic and informatic modelling and ethic and philosophic reflection on our project ; this aspect interested Dr. Nicolas very much.<br/>
 +
We then described our experimental strategy to create a bacteria that can chelate iron: our goal is to design a bacteria that produces a massive amount of siderophores when iron from food arrives.<br/>
 +
We then presented the different parts of modelling: bacterial growth of our bacteria, risks for patients, amount of absorbed chelated, modelling of the intestine.<br/>
 +
Finally we discussed the use of microfluidics to study the ability of our bacteria to chelate iron.<br/><br/>
 +
 +
Gaël Nicolas then focused on some points:
 +
<ul>
 +
<li>Naturally, there are not a lot of bacteria in the duodenum (only 10 to 100 bacteria for each gram
 +
of matter). But we underlined that could be an advantage for our project, and Dr. Nicolas agreed with us.
 +
 +
<li>Incomplete penetrance (<i>proportion of individuals carrying a particular variant of a gene which express an associated trait</i>) with homozygote HFE C282Y mutation (<i>responsible of more than 95% of genetic <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a></i>). There is a 1:300 proportion of French population that have homozygote HFR C282Y mutation but all of them do not develop <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a>, which reduces the proportion of people that could be interested by our treatment.
 +
 +
<li><a href="http://2013.igem.org/Team:Evry/Project_diseases#Thalassemia">Thalassemia</a> seems like more appropriate for the application of our project. <a href="http://2013.igem.org/Team:Evry/Project_diseases#Thalassemia">Thalassemia</a> is severe anemia due to a defect in hemoglobin’s globin (alpha or beta) production. There is a default of red cells production. The only way to treat this anemia is blood transfusion. But each transfusion also provides a huge amount of iron: 200 mg (as total iron in human body is between 3 and 5 grams, the mass of a nail!). After a dozen transfusions, patients develop a secondary iron overload also called secondary <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a> (<i>secondary to transfusion</i>).<br/>
 +
Furthermore, their organisms “misinterpret” this anemia: anemia is perceived as a result of lack of iron. Hence, there is a repression of hepcidin hormone synthesis (<i>which regulates negatively iron absorption in the intestines</i>).<br/>
 +
The consequence is that there is a massive absorption of alimentary iron (10 to 20 times more than a healthy person). Due to this iron absorption, iron overload in blood is even more important, it is a vicious circle! This is really terrible since, because of their anemia, bloodletting is impossible!<br/>
 +
The only treatment to decrease this dangerous iron overload is the administration by perfusion of an iron chelator, 12 hours a day, 5 days a week; which is very difficult for patients.
 +
Oral iron chelator Exjade (Deferasirox) is very problematic because of the important side effects (e.g. renal failure). It is actively keep under surveillance by the French Agency for the Safety of Health Products (APFSAP).
 +
Iron chelator treatments are used during the whole life of <a href="http://2013.igem.org/Team:Evry/Project_diseases#Thalassemia">thalassemia</a> patients because most of them die of iron overload, more than from anemia. <a href="http://2013.igem.org/Team:Evry/Project_diseases#Thalassemia">Thalassemia</a> patients are people who have a very important disease and alternative treatment would be a good thing.
 +
<li>Gaël Nicolas also told us that heminic iron (<i>from meat</i>) is very important source of iron, we have to take that into account.
 +
<li> He finally reminded us to check affinities of aerobactin and enterobactin (<i>two bacterial siderophors</i>) for iron.
 +
</ul>
 +
<br/><br/>
 +
 +
 +
<p>We then opened a discussion and a series of questions and answers:<br/>
 +
<b>Q1: How much iron can a hemochromatosis patient absorb? </b><br/>
 +
10 times the amount of a healthy person. A balanced diet of a European type provides 20 milligram of iron but just 1 milligram is absorb by organism. In <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a> patient, it could go to 10 milligrams and even higher in severe cases.<br/>
 +
<b> Q2: Would it be interesting to act directly on the hepcidin hormone? </b><br/>
 +
Yes, but I think it would be a little “off-topic”, unless you found a bacteria that directly acted on hepcidin (hepcidin is also an anti-microbial peptide), its expression is increased during inflammation. <br/>
 +
<b>Q3: Would it be interesting to scavenger Fe<sup>3+</sup> iron in food ? </b><br/>
 +
Yes, that would be a good idea. You could also think to inactivate a protein implied in iron transport by duodenum enterocytes <br/>
 +
<b> Q4: What is the affinity of ferroportine (<i>iron-regulated transporter that transport iron from intestine cells to blood</i>) for iron? </b><br/>
 +
We still have no idea! The 3D structure of Ferroportin is still unknown, 15 years after its discovery and there is still a controversy about the localization of it C-terminal extremity. <br/>
 +
<b>Q5: Is there a mouse model for hemochromatosis available in your laboratory? And could we possibly use it?</b><br/>
 +
Yes, totally, you could use it. <br/>
 +
<b>Q6: How could we give our bacteria to the mouse?</b><br/>
 +
The simplest way would be by forced-feeding. <br/>
 +
<b>Q7: Is this something you know how to do?</b><br/>
 +
Yes sure.<br/>
 +
<b>Q8: Would it be interesting to model iron homeostasis in mammals? </b><br/>
 +
Yes, it would be a great idea! Furthermore is largely uncharted territory! I have also no doubts that microbiote iron homeostasis and mammal iron homeostasis are link. It will be a very productive topic in the next years. Each project and each project will provide data about it. A journey of a thousand miles begins with a single step!<br/><br/></p>
 +
 +
<p>Dr Nicolas gives us a review he made on iron homeostasis in mammals (mouse and human). The review is only available in french and was made for non-scientist, you can find it there (link of the pdf).<br/>
 +
 +
Gaël Nicolas then give us detail about french patient association and contacts. He also encourages us to contact Professor Pierre Brissot, who is a doctor and a researcher constantly in contact with patients.<br/><br/>
 +
 +
Gaël Nicolas wished us to enjoy our project realization and that iGEM strengthen our scientific interest, and finally he wished us good luck for the competition.</p>
 +
 +
 +
<h2>The clinical point of view</h2>
 +
 +
<h3>Discussing with Professor P. Brissot, a specialist clinician</h3>
 +
 +
<img src='http://www.tif2013.org/wp-content/uploads/2013/05/Prof-P-Brissot-picture-website.png' alt='Pierre Brissot' align='right' style="margin-left:20px;" height='150px'/>
 +
 +
<p> Pierre Brissot est un Professeur universitaire et un practicien hospitalier au CHU de Pontchaillou à Rennes, il est le Responsable du Centre National de Référence des Surcharges en Fer Rares d’Origine Génétique et il est un des fondateurs de l'<a href="http://efaph.eu/">EFAPH</a> (European Federation of Association of Patients with Haemochromatosis). Grâce à son expérience de clinicien, il a pu nous conseillé sur notre projet, notamment sur le diagnostic de la maladie et son traitement. Tout comme Gaël Nicolas, il a trouvé notre projet innovant et éventuellement réalisable. (See <a href="http://2013.igem.org/Team:Evry/Seminar#Feel">les ressentis du séminaire</a>
 +
</p>
 +
 +
<div style="clear:both;"></div>
 +
 +
<h3>Asking the president of patients' associations </h3>
 +
 +
 +
<img src='http://2013.igem.org/wiki/images/9/98/Hemochr.jpg' alt='RDV 04/09/2013' align='left' style="margin-right:20px;" height='300px'/>
 +
 +
<p>Hervé Ségalen is the president of the <a href="http://sites.google.com/site/hemochromatoseiledefrance/" target='_blank'>AHP</a> (Association Hemochromatose Paris île de France) that we contacted in July. He edited our survey in order to make it understandable by <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a> patients, and gave us his opinion on our project as a <a href="http://2013.igem.org/Team:Evry/Project_diseases#Hemochromatosis">hemochromatosis</a> patient. Finally, he passed on our survey to the patients who are part of the AHP association.</p>
 +
 +
<p>Brigitte Pineau is the president of <a href="http://www.hemochromatose.org/" target='_blank'>FFAMH</a> (Fédération Française des Associations de Malades de l'Hémochromatose- French Federation of Hemochromatosis patients' unions). She also passed on our survey to patients, as well as to Professor Henri Michel, president of the <a href="http://www.hemochromatose.fr/" target='_blank'>AHF</a>  (Association Hémochromatose France - France Hemochromatosis association). On the 4th of September, we met Brigitte Pineau and Hervé Ségalen in order to prepare the seminar we organized on the 18th of September and to explain our project to them in more detail.
 +
</p>

Revision as of 00:45, 29 October 2013

Iron coli project

Consultation d'experts

Lors de ce projet, nous avons établi un contact avec différents experts de l'hémochromatose : des patients, des chercheurs spécialistes du métabolisme du fer et des cliniciens.

The scientific point of view

Gaël Nicolas

Professor Gaël Nicolas is a French scientist who is working on the regulation of hepcidin expression. He described in 2001 for the first time the role of this hormone in the regulation of iron homeostasis in mammals.
(See Gaël Nicolas resume for more information)

The meeting took place at Cochin Institut, on the 18 June 2013.


We first presented the aim of iGEM competition and iGEM Evry team to Gaël Nicolas. We mentioned the pluridisciplinary aspect of iGEM: biology, engineering, mathematic and informatic modelling and ethic and philosophic reflection on our project ; this aspect interested Dr. Nicolas very much.
We then described our experimental strategy to create a bacteria that can chelate iron: our goal is to design a bacteria that produces a massive amount of siderophores when iron from food arrives.
We then presented the different parts of modelling: bacterial growth of our bacteria, risks for patients, amount of absorbed chelated, modelling of the intestine.
Finally we discussed the use of microfluidics to study the ability of our bacteria to chelate iron.

Gaël Nicolas then focused on some points:

  • Naturally, there are not a lot of bacteria in the duodenum (only 10 to 100 bacteria for each gram of matter). But we underlined that could be an advantage for our project, and Dr. Nicolas agreed with us.
  • Incomplete penetrance (proportion of individuals carrying a particular variant of a gene which express an associated trait) with homozygote HFE C282Y mutation (responsible of more than 95% of genetic hemochromatosis). There is a 1:300 proportion of French population that have homozygote HFR C282Y mutation but all of them do not develop hemochromatosis, which reduces the proportion of people that could be interested by our treatment.
  • Thalassemia seems like more appropriate for the application of our project. Thalassemia is severe anemia due to a defect in hemoglobin’s globin (alpha or beta) production. There is a default of red cells production. The only way to treat this anemia is blood transfusion. But each transfusion also provides a huge amount of iron: 200 mg (as total iron in human body is between 3 and 5 grams, the mass of a nail!). After a dozen transfusions, patients develop a secondary iron overload also called secondary hemochromatosis (secondary to transfusion).
    Furthermore, their organisms “misinterpret” this anemia: anemia is perceived as a result of lack of iron. Hence, there is a repression of hepcidin hormone synthesis (which regulates negatively iron absorption in the intestines).
    The consequence is that there is a massive absorption of alimentary iron (10 to 20 times more than a healthy person). Due to this iron absorption, iron overload in blood is even more important, it is a vicious circle! This is really terrible since, because of their anemia, bloodletting is impossible!
    The only treatment to decrease this dangerous iron overload is the administration by perfusion of an iron chelator, 12 hours a day, 5 days a week; which is very difficult for patients. Oral iron chelator Exjade (Deferasirox) is very problematic because of the important side effects (e.g. renal failure). It is actively keep under surveillance by the French Agency for the Safety of Health Products (APFSAP). Iron chelator treatments are used during the whole life of thalassemia patients because most of them die of iron overload, more than from anemia. Thalassemia patients are people who have a very important disease and alternative treatment would be a good thing.
  • Gaël Nicolas also told us that heminic iron (from meat) is very important source of iron, we have to take that into account.
  • He finally reminded us to check affinities of aerobactin and enterobactin (two bacterial siderophors) for iron.


We then opened a discussion and a series of questions and answers:
Q1: How much iron can a hemochromatosis patient absorb?
10 times the amount of a healthy person. A balanced diet of a European type provides 20 milligram of iron but just 1 milligram is absorb by organism. In hemochromatosis patient, it could go to 10 milligrams and even higher in severe cases.
Q2: Would it be interesting to act directly on the hepcidin hormone?
Yes, but I think it would be a little “off-topic”, unless you found a bacteria that directly acted on hepcidin (hepcidin is also an anti-microbial peptide), its expression is increased during inflammation.
Q3: Would it be interesting to scavenger Fe3+ iron in food ?
Yes, that would be a good idea. You could also think to inactivate a protein implied in iron transport by duodenum enterocytes
Q4: What is the affinity of ferroportine (iron-regulated transporter that transport iron from intestine cells to blood) for iron?
We still have no idea! The 3D structure of Ferroportin is still unknown, 15 years after its discovery and there is still a controversy about the localization of it C-terminal extremity.
Q5: Is there a mouse model for hemochromatosis available in your laboratory? And could we possibly use it?
Yes, totally, you could use it.
Q6: How could we give our bacteria to the mouse?
The simplest way would be by forced-feeding.
Q7: Is this something you know how to do?
Yes sure.
Q8: Would it be interesting to model iron homeostasis in mammals?
Yes, it would be a great idea! Furthermore is largely uncharted territory! I have also no doubts that microbiote iron homeostasis and mammal iron homeostasis are link. It will be a very productive topic in the next years. Each project and each project will provide data about it. A journey of a thousand miles begins with a single step!

Dr Nicolas gives us a review he made on iron homeostasis in mammals (mouse and human). The review is only available in french and was made for non-scientist, you can find it there (link of the pdf).
Gaël Nicolas then give us detail about french patient association and contacts. He also encourages us to contact Professor Pierre Brissot, who is a doctor and a researcher constantly in contact with patients.

Gaël Nicolas wished us to enjoy our project realization and that iGEM strengthen our scientific interest, and finally he wished us good luck for the competition.

The clinical point of view

Discussing with Professor P. Brissot, a specialist clinician

Pierre Brissot

Pierre Brissot est un Professeur universitaire et un practicien hospitalier au CHU de Pontchaillou à Rennes, il est le Responsable du Centre National de Référence des Surcharges en Fer Rares d’Origine Génétique et il est un des fondateurs de l'EFAPH (European Federation of Association of Patients with Haemochromatosis). Grâce à son expérience de clinicien, il a pu nous conseillé sur notre projet, notamment sur le diagnostic de la maladie et son traitement. Tout comme Gaël Nicolas, il a trouvé notre projet innovant et éventuellement réalisable. (See les ressentis du séminaire

Asking the president of patients' associations

RDV 04/09/2013

Hervé Ségalen is the president of the AHP (Association Hemochromatose Paris île de France) that we contacted in July. He edited our survey in order to make it understandable by hemochromatosis patients, and gave us his opinion on our project as a hemochromatosis patient. Finally, he passed on our survey to the patients who are part of the AHP association.

Brigitte Pineau is the president of FFAMH (Fédération Française des Associations de Malades de l'Hémochromatose- French Federation of Hemochromatosis patients' unions). She also passed on our survey to patients, as well as to Professor Henri Michel, president of the AHF (Association Hémochromatose France - France Hemochromatosis association). On the 4th of September, we met Brigitte Pineau and Hervé Ségalen in order to prepare the seminar we organized on the 18th of September and to explain our project to them in more detail.